Related Experiment Videos
Statin therapy: where are we? Where do we go next?
1Weill Medical College of Cornell University, Cornell University, New York, New York 10021, USA.
Insights
Statin therapy effectively lowers coronary artery disease risks. Beyond cholesterol, apolipoproteins B and A-I, plus triglycerides and HDL-C, are crucial for accurate cardiovascular risk assessment.
Area of Science:
- Cardiology
- Preventive Medicine
- Biochemistry
Background:
- Statin therapy is proven to reduce coronary artery disease (CAD) morbidity and mortality.
- The link between lowering total and low-density lipoprotein cholesterol (LDL-C) and CAD prevention is well-established.
- Accurate global risk assessment requires incorporating factors beyond traditional cholesterol levels.
Purpose of the Study:
- To evaluate the predictive value of on-treatment apolipoproteins B and A-I in patients with average cholesterol levels and reduced high-density lipoprotein cholesterol (HDL-C).
- To highlight the importance of triglycerides and HDL-C in CAD risk assessment.
- To identify challenges in refining global cardiovascular risk assessment for clinical practice.
Main Methods:
- Analysis of outcomes from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) primary prevention trial.
- Inclusion of patients with average cholesterol levels and low HDL-C.
- Review of data from fibrate therapy trials and other relevant studies.
Main Results:
- On-treatment apolipoproteins B and A-I levels are important predictors of first major cardiovascular events in specific patient populations.
- Triglycerides and HDL-C levels are significant contributors to coronary artery disease risk.
- Existing risk assessment models may not fully capture the global cardiovascular risk.
Conclusions:
- Future treatment guidelines must incorporate novel risk factors like apolipoproteins, triglycerides, and HDL-C for comprehensive CAD risk assessment.
- Refining global risk measurement and simplifying its clinical application are essential.
- Personalized risk assessment considering multiple biomarkers is crucial for effective lifestyle and drug therapy interventions.
Abstract:
Statin therapy reduces coronary artery disease morbidity and mortality in primary and secondary prevention trials including patients with elevated and average cholesterol levels. The association between reduction of total or low-density lipoprotein cholesterol and preventive benefit is well established. However, additional risk factors for coronary artery disease need to be incorporated into risk assessment to provide an accurate measure of global risk for use in lifestyle intervention and drug therapy guidelines. Assessment of outcomes in the Air Force/Texas Coronary Atherosclerosis Prevention Study primary prevention trial, which involved patients with average cholesterol levels and reduced high-density lipoprotein cholesterol (HDL-C), suggests the importance of on-treatment values of apolipoproteins B and A-I in predicting first major events in such a population. Other data, including trials of fibrate therapy showing reduction in coronary artery disease events, support the importance of triglycerides and HDL-C in coronary artery disease risk. Challenges for future treatment guidelines include incorporation of emerging and novel risk factors into risk assessment, refinement of global risk measurement, and simplification for application to clinical practice.